Published in:
01-09-2021 | Anticoagulant | Concise Research Report
Oral Anticoagulant Use in a Racial and Ethnically Diverse Population with Atrial Fibrillation
Authors:
Ankur Srivastava, BA, Eric Sun, MD, Aliasakar Hasani, MD, John D. Fisher, MD, Kevin J. Ferrick, MD, Andrew K. Krumerman, MD
Published in:
Journal of General Internal Medicine
|
Issue 9/2021
Login to get access
Excerpt
Warfarin is an established therapy to prevent ischemic stroke in patients with atrial fibrillation.
1 Direct oral anticoagulants (DOACs) have emerged as alternative therapies due to favorable risk-benefit profiles compared with warfarin.
1 Many patients with atrial fibrillation that meet guideline recommended criteria, especially Black and Hispanic patients, are not treated with anticoagulants.
2 Several investigators have noted differences in oral anticoagulant treatment for atrial fibrillation in Black and Hispanic patients compared with their white counterparts.
2, 3 However, a major shortcoming of these studies is the limited representation of patients of color. …
